Table 1 Baseline Data at Inclusion in Original Cohort 2003–2005 for the 237 Included Participants with Toxic Nodular Goiter in the Follow-Up 2011–2013 and for the 118 Individuals Who Did Not Reply to the Study Invitation (Nonrepliers)
Included | Non-repliers | |||
|---|---|---|---|---|
(n = 237) | (n = 118) | p | ||
Gender | ||||
Women, n (%) | 205 (86.5) | 99 (83.9) | 0.511 | |
Men, n (%) | 32 (13.5) | 19 (16.1) | ||
Age | ||||
Total mean years [SD] | 62.1 [11.7] | 60 [16.3] | 0.170 | |
Women mean years [SD] | 61.6[11.7] | 59.7[16.9] | 0.251 | |
Men mean years [SD] | 65.1[11.2] | 61.6[13.6] | 0.325 | |
Country of origin | (n = 237) | (n = 70) | ||
Sweden, n (%) | 202 (85.2) | 55 (78.6) | 0.185 | |
Europe outside Sweden, n (%) | 22 (9.3) | 5 (7.1) | 0.579 | |
Outside Europe, n (%) | 13 (5.5) | 10 (14.3) | 0.014 | |
Smoking at diagnosis | (n = 234) | (n = 106) | ||
Non-smoker, n (%) | 91 (38.9) | 46 (43.4) | 0.433 | |
Former smoker, n (%) | 72 (30.8) | 32 (30.2) | 0.914 | |
Smoking at diagnosis, n (%) | 71 (30.3) | 28 (26.4) | 0.460 | |
Eye symptoms | (n = 237) | (n = 117) | ||
No Eye symptoms, n (%) | 235 (99.2) | 116 (99.1) | 0.992 | |
Eye symptoms, n (%) | 2 (0.8) | 1 (0.9) | ||
Initial treatment | (n = 237) | (n = 53) | ||
ATD, n (%) | 40 (16.9) | 17 (32.1) | 0.012 | |
RAI, n (%) | 167 (70.5) | 33 (62.3) | 0.243 | |
Surgery, n (%) | 14 (5.9) | 3 (5.7) | 0.945 | |
Conservative, n (%) | 16 (6.8) | 0 | 0.052 | |